Proactive Investors - Run By Investors For Investors

AngioDynamics fiscal 2Q results boosted by oncology sales

In the quarter, the company advanced its efforts to apply its NanoKnife system in the fight against pancreatic cancer
A form stating a diagnosis of pancreatic cancer
The Latham, New York-based company recently acquired RadiaDyne, a privately-held medical diagnostic and device company

AngioDynamics (NASDAQ:ANGO) zipped past Wall Street’s estimates for both revenue and profit in its fiscal second quarter on the back of a recent acquisition and robust sales from its oncology business.

In the three months ended November 30, the medical device provider posted a profit of $2.1 million, or $0.06 per share, up from earnings of $200,000, or $0.01 per share, posted in the year-ago quarter. On an adjusted basis, its per-share earnings beat analysts’ consensus estimate by a penny, coming in at $0.22 per share.

Revenue jumped to $91.5 million in the quarter, which also exceeded the average estimate of $89.2 million projected by Wall Street.

AngioDynamics is a provider of minimally-invasive medical devices used for vascular access, peripheral vascular disease and oncology.

READ: AngioDynamics falls short of Street's fiscal 1Q earnings estimate due to sluggish oncology device sales

In the quarter, the Latham, New York-based company acquired RadiaDyne, a privately held medical diagnostic and device company that designs patient dose monitoring technology to improve cancer treatment.

The company also advanced its efforts to apply its NanoKnife system in the fight against pancreatic cancer. The US Food and Drug Administration recently notified AngioDynamics that NanoKnife will be considered a Category B IDE once approval is received to begin its Direct NanoKnife study for Stage III pancreatic cancer, noted Jim Clemmer, AngioDynamics’ CEO in a statement.

“Our quarterly performance was positively impacted by our recent acquisitions, validating our portfolio optimization strategy and enhancing our value proposition within oncology,” Clemmer added.

The company’s net sales from its oncology business came to $15.3 million, up 19.8% from the $12.8 million posted in the year-ago quarter, thanks partly to robust NanoKnife sales.

Looking ahead, the company expects full-year earnings in the range of $0.82  to $0.86 per share, with revenue falling between $354 million and $359 million.

AngioDynamics shares held steady in Friday’s pre-market session to hit $19.42.

View full ANGO profile View Profile

AngioDynamics Timeline

Related Articles

scientist looking through microscope
April 11 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price
Weight loss
January 07 2019
A deal with Indian firm Zeon Lifesciences in January is the ninth deal the firm has secured for the weight loss product
PT exercises
December 19 2018
The Californian company is a bet on an industry that is in need of transformation
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use